The Most Disruptive Molecule in Medicine Today

Where cannabis-based treatment is available, traditional pharmaceuticals lose out. The primary takeaway is that cannabis, even in these early stages of research, has already distinguished itself as a major force. [Wealth Daily logo] The Most Disruptive Molecule in Medicine Today [Alex Koyfman Photo] By [Alex Koyfman]( Written Thursday, September 21, 2017 Personally, I love a good chart. There's nothing like a well-designed infographic to put relevant data into the proper context and illustrate a point. One of the best and most telling charts I've seen in the last few weeks is pictured below. [cannachart] As you can see, this chart tracks the rate of pill prescription in states where cannabis has been cleared to use as an alternative medical treatment for some of the most common physical and psychological conditions. The difference is stark, especially when taking into account that the first item on the list not only shows the biggest disparity but also pertains to a class of drug now responsible for a growing epidemic sweeping the nation: opioid abuse. America's NEW Pot Haven It could become the largest medical marijuana market in America, behind California. In fact, the state has projected it to be a $2 billion market by 2020. And this little firm is positioned to be a first mover in this burgeoning cannabis market. Imagine 10 football fields... filled with weed. And it’s all perfectly legal! The best part is that you can invest in this tiny company today for just pennies. [Click here for details.]( Just as the Car Put an End to the Horse and Carriage... The primary lesson behind this chart is that in markets where cannabis-based treatment is available, traditional pharmaceuticals lose out, decidedly. And the primary takeaway is that cannabis, even in these early stages of research and development within the mainstream pharmaceutical industry, has already distinguished itself as a major force... Perhaps the strongest single force, in fact, since the advent of modern antibiotics in the first half of the 20th century. Unfortunately, up until very recently, legislation, as well as carefully trained public opinion, prevented tetrahydrocannabinol (THC) — the active ingredient in cannabis — from being the focus of legal scientific research. I won't go into detail as to why there was a very active propaganda campaign against the plant back in the ’20s and ’30s, but, suffice it to say, the basis was purely political. The result was that up until virtually the late 1990s, THC and its parent plant were completely off-limits to scientific research... a sad fact considering how much mere decriminalization of the raw plant itself could have helped a wide spectrum of potential users. Today, however, we're making up for lost time. 70 Years Wasted? More Like 70 Years of Build-Up So much so that the current trend to reform prohibition has sparked an unprecedented bull market in all things cannabis-related, from the most serious of medical research right on down to the sale of paraphernalia used in recreational consumption. Here is another chart, to put a visual to that fact. [cannachart] That's no mistake, folks — what you're looking at is a 23x market expansion, by dollar value, over 14 years, with similar growth in the consumer pool as well. I'm hard-pressed to come up with anything that's grown that much, that fast in recent history... except for one other technological sector: the internet. A world-altering technological revolution, the rise of the internet changed the face of the economy in just about every aspect. This third and final chart shows the growth in the internet market, in terms of users, between the early 1990s and 2014. [cannachart] A 23x (2,300%) improvement in overall users took place, roughly between 1997 and 2014, as the total global population of internet users went from about 150 million to 3 billion. That growth propelled Amazon (NASDAQ: AMZN) from a share price of $1.54 in 1997 to $967 today. And yet this historic rise still lags behind performance projections for the newly awakened cannabis market, which will accomplish the same degree of growth in three fewer years. Of course, there are still plenty fighting the changes, but, as countless lessons in the adoption of new technology have shown, this hesitation is only temporary. Total Returns of 3,194% Only one man I’ve seen has a portfolio that’s sitting on raw returns of 3,194%. So it’s no coincidence that Barron’s ranked him as their #1 Money Manager. Thing is, today he’s revealing a stock he’s touting as the “Next Berkshire.” [Click here to get in before this stock pays out 109 times your money.]( It's Not Just for Fun Anymore Today, cannabis is more than just something the bad kids at your children's school do while cutting class. It's the raw material in more products than I can list here, including some of today's most cutting-edge and promising pharmaceutical agents. Medicines designed to combat diseases that medical science had previously dismissed as "untreatable" are now opening doors to possibilities never before imagined. In fact, the potential is very real that by the year 2030, diseases like Parkinson's and Alzheimer's will have been defeated with THC-derived medicines... Medicines that, just a few decades ago, would have been invalidated by legislation before their potential could be unlocked. This Is Still Just the Start If you think cannabis and cannabinoid products are a hot topic today, you haven't seen anything yet. Conservatively speaking, this market still has a 15x (1,500%) expansion to achieve before any sort of plateau is to be expected. That means it's not too late to be on the ground floor as this industry goes mainstream. Remember, there are still dozens of states left to reform their prohibitive legislation, which means there are dozens of built-in catalysts just waiting to be realized. And, of course, the ultimate outcome — federal deregulation — can and will take hold, probably within the next decade if not sooner. After almost 20 years in the investment business, I have to say I've never seen anything quite like it. I've never seen stocks move so fast or progress made this rapidly in the development of new enterprises and products. That said, with all the interest in the sector, one thing is inevitable: there will be far more choices than legitimate investment ideas. It's a problem commonly associated with aggressively growing markets, and one that must be endured until the natural selection process filters out all the duds. Having seen plenty of duds in my career, I decided to take a bite out of this as early as possible. And so I recently drafted a report, detailing what I think are three of the most prospective plays in the cannabis industry today. The three companies cover a broad range of products, ranging from THC-derived medicines to dispensers for recreational product. It's almost like a mini ETF for cannabis stocks, and the long-term potential is off the charts. [To access that report immediately, click here.]( Fortune favors the bold, [alex koyfman Signature] Alex Koyfman [[follow basic]@AlexKoyfman on Twitter]( Coming to us from an already impressive career as an independent trader and private investor, Alex's specialty is in the often misunderstood but highly profitable development-stage microcap sector. Focusing on young, aggressive, innovative biotech and technology firms from the U.S. and Canada, Alex has built a track record most Wall Street hedge funders would envy. Alex contributes his thoughts and insights regularly to [Wealth Daily](. To learn more about Alex, [click here](. Enjoy reading this article? [Click here]( to like it and receive similar articles to read! Browse Our Archives [Is Facebook a Monopoly?]( [Roku Aims for $252 Million for its IPO]( [Investing in the iPhone X: The Stocks Behind the Curtain]( [Bitcoin Just Collapsed. Should You Buy?]( [The World's Most Important Metal]( --------------------------------------------------------------- This email was sent to {EMAIL} . It is not our intention to send email to anyone who doesn't want it. If you're not sure why you've received this e-letter, or no longer wish to receive it, you may [unsubscribe here](, and view our privacy policy and information on how to manage your subscription. To ensure that you receive future issues of Wealth Daily, please add wd-eletter@angelnexus.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance. [Wealth Daily](, Copyright © 2017, [Angel Publishing LLC](. All rights reserved. 111 Market Place #720 Baltimore, MD 21202. The content of this site may not be redistributed without the express written consent of Angel Publishing. Individual editorials, articles and essays appearing on this site may be republished, but only with full attribution of both the author and Wealth Daily as well as a link to www.wealthdaily.com. Your privacy is important to us -- we will never rent or sell your e-mail or personal information. [View our privacy policy here.]( No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. [Wealth Daily]( does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question.